Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy

M. Takeda, I. Okamoto, K. Sakai, H. Kawakami, K. Nishio, K. Nakagawa

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: The EML4-ALK fusion oncogene represents a recently identified molecular target in a subset of patients with non-small-cell lung cancer (NSCLC). Limited data have been available, however, on the outcome of first-line platinum-based chemotherapy in patients with EML4-ALK-positive advanced NSCLC who have not been treated with an ALK kinase inhibitor. Patients and methods: The efficacy of platinum-based chemotherapy was compared between patients with advanced nonsquamous NSCLC who harbor EML4-ALK and those who harbor EGFR mutations and those with neither molecular abnormality. Results: Among 200 patients with advanced nonsquamous NSCLC, 18 (9.0%) were positive for EML4-ALK, 31 (15.5%) harbored EGFR mutations, and 151 (75.5%) were wild type for both abnormalities. Platinum-based combination chemotherapy showed similar efficacies in the EML4-ALK, EGFR mutation, and wild-type cohorts in terms of response rate and progression-free survival, and overall survival in the EML4-ALK cohort closely resembled that in the wild-type cohort. Within the EML4-ALK cohort, patients with variants 1 or 3 of the fusion gene were predominant and did not appear to differ in their sensitivity to the platinum-based regimens. Conclusion: Patients with EML4-ALK-positive advanced NSCLC manifest an aggressive clinical course similar to that of those with wild-type tumors if the effective targeted therapy is not instituted.

Original languageEnglish
Article numbermds124
Pages (from-to)2931-2936
Number of pages6
JournalAnnals of Oncology
Volume23
Issue number11
DOIs
Publication statusPublished - Nov 1 2012

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Mutation
Oncogene Fusion
Gene Fusion
Combination Drug Therapy
Disease-Free Survival
Phosphotransferases
Survival
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. / Takeda, M.; Okamoto, I.; Sakai, K.; Kawakami, H.; Nishio, K.; Nakagawa, K.

In: Annals of Oncology, Vol. 23, No. 11, mds124, 01.11.2012, p. 2931-2936.

Research output: Contribution to journalArticle

@article{6be3b434e20d466b80b80b01e26264e3,
title = "Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy",
abstract = "Background: The EML4-ALK fusion oncogene represents a recently identified molecular target in a subset of patients with non-small-cell lung cancer (NSCLC). Limited data have been available, however, on the outcome of first-line platinum-based chemotherapy in patients with EML4-ALK-positive advanced NSCLC who have not been treated with an ALK kinase inhibitor. Patients and methods: The efficacy of platinum-based chemotherapy was compared between patients with advanced nonsquamous NSCLC who harbor EML4-ALK and those who harbor EGFR mutations and those with neither molecular abnormality. Results: Among 200 patients with advanced nonsquamous NSCLC, 18 (9.0{\%}) were positive for EML4-ALK, 31 (15.5{\%}) harbored EGFR mutations, and 151 (75.5{\%}) were wild type for both abnormalities. Platinum-based combination chemotherapy showed similar efficacies in the EML4-ALK, EGFR mutation, and wild-type cohorts in terms of response rate and progression-free survival, and overall survival in the EML4-ALK cohort closely resembled that in the wild-type cohort. Within the EML4-ALK cohort, patients with variants 1 or 3 of the fusion gene were predominant and did not appear to differ in their sensitivity to the platinum-based regimens. Conclusion: Patients with EML4-ALK-positive advanced NSCLC manifest an aggressive clinical course similar to that of those with wild-type tumors if the effective targeted therapy is not instituted.",
author = "M. Takeda and I. Okamoto and K. Sakai and H. Kawakami and K. Nishio and K. Nakagawa",
year = "2012",
month = "11",
day = "1",
doi = "10.1093/annonc/mds124",
language = "English",
volume = "23",
pages = "2931--2936",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy

AU - Takeda, M.

AU - Okamoto, I.

AU - Sakai, K.

AU - Kawakami, H.

AU - Nishio, K.

AU - Nakagawa, K.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Background: The EML4-ALK fusion oncogene represents a recently identified molecular target in a subset of patients with non-small-cell lung cancer (NSCLC). Limited data have been available, however, on the outcome of first-line platinum-based chemotherapy in patients with EML4-ALK-positive advanced NSCLC who have not been treated with an ALK kinase inhibitor. Patients and methods: The efficacy of platinum-based chemotherapy was compared between patients with advanced nonsquamous NSCLC who harbor EML4-ALK and those who harbor EGFR mutations and those with neither molecular abnormality. Results: Among 200 patients with advanced nonsquamous NSCLC, 18 (9.0%) were positive for EML4-ALK, 31 (15.5%) harbored EGFR mutations, and 151 (75.5%) were wild type for both abnormalities. Platinum-based combination chemotherapy showed similar efficacies in the EML4-ALK, EGFR mutation, and wild-type cohorts in terms of response rate and progression-free survival, and overall survival in the EML4-ALK cohort closely resembled that in the wild-type cohort. Within the EML4-ALK cohort, patients with variants 1 or 3 of the fusion gene were predominant and did not appear to differ in their sensitivity to the platinum-based regimens. Conclusion: Patients with EML4-ALK-positive advanced NSCLC manifest an aggressive clinical course similar to that of those with wild-type tumors if the effective targeted therapy is not instituted.

AB - Background: The EML4-ALK fusion oncogene represents a recently identified molecular target in a subset of patients with non-small-cell lung cancer (NSCLC). Limited data have been available, however, on the outcome of first-line platinum-based chemotherapy in patients with EML4-ALK-positive advanced NSCLC who have not been treated with an ALK kinase inhibitor. Patients and methods: The efficacy of platinum-based chemotherapy was compared between patients with advanced nonsquamous NSCLC who harbor EML4-ALK and those who harbor EGFR mutations and those with neither molecular abnormality. Results: Among 200 patients with advanced nonsquamous NSCLC, 18 (9.0%) were positive for EML4-ALK, 31 (15.5%) harbored EGFR mutations, and 151 (75.5%) were wild type for both abnormalities. Platinum-based combination chemotherapy showed similar efficacies in the EML4-ALK, EGFR mutation, and wild-type cohorts in terms of response rate and progression-free survival, and overall survival in the EML4-ALK cohort closely resembled that in the wild-type cohort. Within the EML4-ALK cohort, patients with variants 1 or 3 of the fusion gene were predominant and did not appear to differ in their sensitivity to the platinum-based regimens. Conclusion: Patients with EML4-ALK-positive advanced NSCLC manifest an aggressive clinical course similar to that of those with wild-type tumors if the effective targeted therapy is not instituted.

UR - http://www.scopus.com/inward/record.url?scp=84868153844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868153844&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds124

DO - 10.1093/annonc/mds124

M3 - Article

C2 - 22771825

AN - SCOPUS:84868153844

VL - 23

SP - 2931

EP - 2936

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

M1 - mds124

ER -